Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.
about
mTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesiaA Mind-Body Approach to Pediatric Pain Management.Anti-nerve growth factor antibody attenuates chronic morphine treatment-induced tolerance in the rat.Opioid use among same-day surgery patients: Prevalence, management and outcomesIs the pain-reducing effect of opioid medication reliable? A psychophysical study of morphine and pentazocine analgesiaAssociation of morphine-induced analgesic tolerance with changes in gene expression of GluN1 and MOR1 in rat spinal cord and midbrain.Changing mechanisms of opiate tolerance and withdrawal during early development: animal models of the human experience.Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations.A Case-Based Approach to Integrating Opioid Pharmacokinetic and Pharmacodynamic Concepts in Cancer Pain Management.Effects of Short-Term Oxycodone Maintenance on Experimental Pain Responses in Physically Dependent Opioid Abusers.Opioid maintenance, weaning and detoxification techniques: where we have been, where we are now and what the future holds.Patterns of opioid use in sickle cell disease.The dilemma of opioid-induced hyperalgesia and tolerance in chronic opioid therapy.Pharmacokinetic/Pharmacodynamic Relationship of Gabapentin in a CFA-induced Inflammatory Hyperalgesia Rat Model.Effects of microRNA-223 on morphine analgesic tolerance by targeting NLRP3 in a rat model of neuropathic pain.Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methodsRole of fosaprepitant, a neurokinin Type 1 receptor antagonist, in morphine-induced antinociception in ratsCaffeine increases the motivation to obtain non-drug reinforcers in rats.Treating chronic pain: the need for non-opioid options.Opioid-based micro and nanoparticulate formulations: alternative approach on pain management.Fatal Intoxication with Acetyl Fentanyl.The effects of serotonin/norepinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats.The impact of therapeutic opioid agonists on driving-related psychomotor skills assessed by a driving simulator or an on-road driving task: A systematic review.Assisted suicide by fentanyl intoxication due to excessive transdermal application.Genetic deletion of microglial Panx1 attenuates morphine withdrawal, but not analgesic tolerance or hyperalgesia in mice.Antinociceptive Effects of a Novel α2/α3-Subtype Selective GABAA Receptor Positive Allosteric Modulator.Quantification of Morphine, Codeine, and Thebaine in Home-Brewed Poppy Seed Tea by LC-MS/MS.Chronic morphine exposure potentiates p-glycoprotein trafficking from nuclear reservoirs in cortical rat brain microvessels.Bivalent ligand MCC22 potently attenuates nociception in a murine model of sickle cell disease.The grass is not always greener: a multi-institutional pilot study of marijuana use and acute pain management following traumatic injury.Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D receptor activation using multi-biomarker pharmacokinetic/pharmacodynamic modelling
P2860
Q28081540-D16C1EB5-A5E8-425B-B04F-92DA5B260EC3Q33831728-C45E7FBF-9294-493D-9BB9-4D06D32A2E0AQ36123358-4CBE3E3A-237B-4CEB-9819-D12FDDB9EBB2Q36365115-9EE5F57A-D706-48F1-94D4-2BD0D6734866Q36776297-B5917B46-7E31-47B4-8DB9-971CD15B6672Q37366435-F4C35053-C895-47C4-B342-E54E9D5E5478Q38079201-847C7C88-DA20-49EF-ADC6-5E282A256F8AQ38542687-AE9CF668-F73E-4313-8BA8-F60A383EE53BQ38655206-4CACDD1D-8D7B-49FE-990E-348491247DF5Q38919936-5F5EE694-3899-46EF-8A12-A7DC2D322E89Q39225935-EB11B50B-137C-464C-8624-61216114B214Q39551420-EC7CA030-B388-489C-A89C-E5BE2E048C84Q39600032-768FCFF6-ECC4-48CE-B748-0EAB6A5160C9Q40094164-5572E586-C8F9-46AD-9E18-A08CCB19142EQ41763075-A00C4109-38D8-4419-BD8A-54F7096CDEE0Q41775229-18606D52-CC89-4275-B4AF-CDFEE83C89B3Q41950284-A4B3C955-1243-485A-8FEA-57083C0C6ABFQ42214928-AB54E54B-F207-4178-89B1-A8769AB55A19Q43061966-22E16B99-899C-4D01-B185-EDA2F2B03170Q44334825-99E81485-24D8-4AF9-BD34-AA6241108CF5Q45019423-306AB8FE-12B8-4CDB-BF61-3547F0CD94EEQ45259825-A63F3A4C-1CD3-47B4-9EE7-83DF3A4B2B4BQ47211115-1D3C3452-285A-4131-9671-F62687D41089Q47906161-87A7BC25-49A3-4A84-B1BA-9180BD39F9BEQ48178751-8108A96F-E9E6-4CA9-8340-4A20B02E7450Q48284984-4231DB27-12C6-49D2-BD13-DAC0F044C8DDQ49647609-F9820485-FF85-4C0F-A773-AA18A0E57D4FQ50133437-56E005FF-9094-4307-816A-17042260093CQ52316849-1BA0E4F8-97F8-4D1F-BDDA-39476274721CQ55342195-FD8398FD-58EE-4F0A-837F-9B696456DDBAQ58780116-17D357AC-66B2-49DF-817A-0196590E3538
P2860
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.
@en
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.
@nl
type
label
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.
@en
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.
@nl
prefLabel
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.
@en
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.
@nl
P2860
P1433
P1476
Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.
@en
P2093
Emily O Dumas
Gary M Pollack
P2860
P2888
P304
P356
10.1208/S12248-008-9056-1
P407
P577
2008-11-07T00:00:00Z
P5875
P6179
1022480735